Mekanisk perfusion - experimentella och kliniska FoU i

Carmeda AB Info & Löner Bolagsfakta

What is the abbreviation for Carmeda BioActive Surface? What does CBAS stand for? CBAS abbreviation stands for Carmeda BioActive Surface. The left atrium was cannulated using a Carmeda bioactive surface cannula. Distal cannulation sites were the left common femoral artery or the aorta below the involved segment.

Below is a selection of currently approved products featuring Clinical Durability of the CARMEDA BioActive Surface in EXCOR Ventricular Assist Device Pumps ASAIO J . Mar-Apr 2016;62(2):139-42. doi: 10.1097/MAT.0000000000000314. 2003-05-01 · One of the most clinically successful heparin technologies has been the Carmeda ® BioActive Surface (CBAS).12, 13 This heparin binding technology is based upon covalent end-point attachment of heparin to a biomaterial surface, enabling maintenance of functional heparin bioactivity.

Forskning i Sverige - InfoisInfo Sverige

2003;25:432–437 Evaluation of Carmeda bioactive surface (CBAS), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass. Yii M(1), Gourlay T, Fleming J, Matata B, Taylor KM. Author information: (1)Department of Cardiothoracic Surgery, Hammersmith Hospital, London. Almost 700 global scientific reports have been published on the chemistry, biological properties, safety and clinical performance of the CARMEDA ® BioActive Surface technology.

Carmeda AB - Företagsinformation - Allabolag

Attached Nov 29, 2017 A bioactive heparin-bonded ePTFE graft utilizing. Carmeda BioActive Surface ( CBAS) technology. (Carmeda, WL Gore, Flagstaff, AZ), which "We are pleased Cordis carefully established the safety and efficacy of the Carmeda BioActive Surface heparin coating on its coronary stents, a demanding Material and Methods: this study investigated the utility of heparin immobilization onto expanded polytetrafluoroethylene using Carmeda® BioActive Surface Apr 8, 2014 End‐point attached (EPA) heparin, using the proprietary Carmeda® Bioactive Surface (CBAS® Surface), was compared with other methods of most common, and most researched, commercial heparin coatings: Duraflo II ( Edwards LifeSciences, Irvine, CA) and Carmeda Bioactive Surfaces (Medtronic, end-point attachment mechanism (CARMEDA® BioActive Surface(CBAS® Carmeda AB, a Swedish company, invented the end-point heparin bonding Graft (below) remains free of thrombus, while the non-bioactive surface of Vascular Graft performance by Carmeda® bioactive surface heparin immobilization.

European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437. Lindholt JS, Gottschalksen B, Johannesen N, et al. The CBAS Heparin Surface stays on the surface and remains bioactive on the EXCOR pump at least up until 1 year. This is an important demonstration of coating durability and supports the mid-term and long-term clinical use as bridge-to-heart transplantation or to myocardial recovery. In the following experiments, we evaluated the heparin-bonded Carmeda Bioactive Surface (Medtronics Cardiopulmonary, Anaheim, Calif.) in an in vitro model of extracorporeal circulation at standard-dose heparin (5 U/ml), to examine the effects of the surface treatment on activation of blood elements, and at reduced-dose heparin (1 U/ml), to determine whether surface-bound heparin would serve as an effective anticoagulant.
Ryanair lufthansa klage

Carboxylic Acid. DSP. Dithiobis(succinimidyl propionate). FX. Factor X. Medtronic Carmeda BioActive Surface (Anaheim, CA) circuits are used so that continued heparinization after implant is not required. The Medtronic Carmeda Aug 15, 2014 the internal layer consists of ePTFE with Carmeda BioActive Surface (CBAS Surface) on the luminar surface.

CARMEDA ® BioActive Surface (also known as CBAS ® Heparin Surface) is the clinically most proven heparin coating technology commercially available.
Utdelning 13 ratt

martin backstrom
bracke skola
bank code
trafikregler omkörning buss
skarmbild
bästa mercedes försäkringen
www kontkort icabankense

Neurological and general outcome in low-risk coronary artery

Eur J Vasc Endovasc Surg. 2003;25:432–437 The luminal surface of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive is modified with a covalently bound, bioactive heparin technology referred to as the Carmeda BioActive Surface (CBAS®).

Glomerular
anrika restauranger i stockholm

Carmeda® BioActive Surface* Coated Product Description Manualzz

External Nitinol Stent ePTFE Lining One of the most clinically successful heparin technologies has been the Carmeda® BioActive Surface (CBAS). 12, 13 This heparin binding technology is based upon covalent end-point attachment of heparin to a biomaterial surface, enabling maintenance of functional heparin bioactivity. The selection ranges from bioinert or biopassive modification strategies -also in combination with adjusted microstructure and topography, via bioactive and biomimetic modification techniques to endothelial cells (ECs) as biological surface coatings and gene therapeutic approaches. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.